Ibrutinib now cheaper for patients [Publish Date: 09/10/2017]
The Leukaemia Foundation welcomes the Federal Government’s announcement that the cancer medicine, IMBRUVICA® (ibrutinib) will be added to Pharmaceutical Benefits Scheme (PBS) from 1 December 2017.
Bill Petch, CEO at the Leukaemia Foundation said this announcement is an important step
The latest on CAR T-cell therapy research [Publish Date: 28/06/2017]
A clinical trial, expected to open in Sydney later this year, will test advancements in chimeric antigen receptor (CAR) T-cell therapy developed in Australia and funded by the Leukaemia Foundation*.
UPDATE: 8 August 2017 - This clinical trial
World-first blood test could provide less invasive and more effective treatments for blood cancer [Publish Date: 20/06/2017]
A world-first “liquid biopsy” could soon offer you direct access to a simple blood test to help in the monitoring and management of your blood cancer treatment.
The blood test promises a new
15 year Holden partnership celebrated [Publish Date: 15/06/2017]
A brand new Astra, Trailblazer and Trax were unveiled at the recent joint celebration acknowledging Holden’s 15 years of support for the Leukaemia Foundation’s Patient Transport Program in Victoria, bringing their fleet support from 17 vehicles to 20.
Australians living with MPN are one step closer to accessing Pegasys treatment [Publish Date: 08/06/2017]
The drug interferon alfa-2a (Pegasys®) was finally listed on the agenda of the Pharmaceutical Benefits Advisory Committee (PBAC) meeting on March 8 and many Australians are awaiting the results of the discussion.
For Nathalie Cook, who was diagnosed with MPN
Ageing population increasing Queensland’s blood cancer burden [Publish Date: 17/01/2017]
Blood cancer death rates in Queensland have soared by a third in just 10 years, a further symptom of the country’s ageing population, according to a new analysis.
The Leukaemia Foundation’s investigation shows the number of Australians dying from blood
Breakthrough cancer drug venetoclax approved for use in Australia [Publish Date: 10/01/2017]
New anti-cancer drug, venetoclax which has the power to ‘melt away’ advanced forms of chronic lymphocytic leukaemia (CLL) was recently granted approval by the Australian Therapeutic Goods Administration (TGA).
The drug will be marketed as VenclextaTM and is
Towards better treatment outcomes in lymphoma by personalising medicine [Publish Date: 01/09/2016]
New directions in treatment for lymphoma are increasingly based on ‘personalised medicine’, which means identifying the best treatment for an individual patient.
The Leukaemia Foundation’s Head of Blood Cancer Support, Anthony Steele, said the overall aim of this approach was to
Targeted therapies offer fresh hope for AML [Publish Date: 22/07/2016]
The results of a clinical trial involving a new combination therapy of Venetoclax and chemotherapy are providing hope for Australians diagnosed with AML
Clinical and translational AML researcher, Dr Andrew Wei and his teams at the Alfred Hospital and Monash University, are optimistic about the combination therapy, with between 60
Car racing greats make comeback! [Publish Date: 10/05/2016]
For the first time in years some of Australia’s well-known Bathurst racing greats will hit the track again, all for a good cause.
Although many would relish the opportunity to see the likes of Peter Brock,